The de-identified health data market is in trends by growing importance of big data analytics in healthcare. De-identified health data is clinical and demographic patient data that has been processed to remove information that could be used to identify an individual patient. This preserves privacy while allowing organizations to analyze aggregated data and glean insights to improve care delivery and research. De-identified health data has uses ranging from detecting disease outbreaks and drug effectiveness to precision medicine research and development of artificial intelligence clinical decision tools.

The Global de-identified health data market is estimated to be valued at US$ 7.51 Bn in 2024 and is expected to exhibit a CAGR of 9.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the de-identified health data are IQVIA, Oracle (Cerner Corporation), Merative (Truven Health Analytics), Optum, Inc., BioTelemetry, Inc., Flatiron Health, Veradigm LLC, Medidata Solutions, Evidation Health, Inc., Komodo Health, Inc., Sundown Solutions, LLC, Clarify Health Solutions, Akrivia Health, Satori Cyber Ltd., Tempus, nference, Ciox Health, HealthVerity, Zebra Medical Vision, and Huma Therapeutics.

De-identified Health Data Market Demand in healthcare for improved outcomes and reduced costs is fueling greater usage of de-identified health data for research, analytics and development of technological innovations. Many organizations are expanding globally to access more de-identified data and broader patient populations for analytics to develop solutions with greater applicability worldwide.

Market key trends

One of the major trends in the de-identified health data market is the increasing focus on real world evidence generation. Real world evidence involves analysis of real patient data collected outside of randomized clinical trials to understand treatment effectiveness and safety. As regulatory bodies increasingly recognize real world data sources, more sponsors, researchers and organizations are leveraging de-identified health data to generate real world evidence on therapies and devices. This is helping bridge the gap between clinical research and clinical practice.

Porter's Analysis

Threat of new entrants: High barrier to entry due to legal compliances, technology requirements and huge investment needed.

Bargaining power of buyers: Low, few buyers for health data.

Bargaining power of suppliers: High, limited number of data suppliers control supply.

Threat of new substitutes: Low, limited substitutes for de-identified health data.

Competitive rivalry: High, presence of large players in global market leads to intense competition.

De-identified Health Data Market Regional Analysis is North America currently holds the largest share in the global de-identified health data market in terms of value due to high adoption of advanced healthcare IT solutions and supportive government initiatives. This region is also projected as the fastest growing market during forecast period.

Asia Pacific region is expected to grow at the highest CAGR from 2024 to 2031. Increasing government focus on development of healthcare infrastructure, rising healthcare expenditure and growing geriatric population driving the market growth in Asia Pacific region. Growing digitalization of healthcare sector also fueling the demand for de-identified health data in countries like China and India.

About Author:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163)